Journal
EUROPEAN JOURNAL OF CANCER
Volume 106, Issue -, Pages 144-159Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2018.11.002
Keywords
NSCLC; Immunotherapy; Predictive biomarkers; Lung cancer; PD-L1; Tumour mutational burden; Tumour microenvironment; Microsatellite instability
Categories
Ask authors/readers for more resources
Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available